Cataract
Drug research and approvals for cataract: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 20, 2026, 142 studies of cataract are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and the EU has 2 authorised medicines for it.
- Recruiting worldwide: 142
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 2
- A Multi Center Evaluation of TearCare on Surgical Measurements Before Cataract SurgeryNCT07928986 · Not reported · Cleveland Eye Clinic · starts Sep 22, 2026
- Rotational Stability of the Acunex Vario ToricNCT07925840 · Not applicable · Prim. Prof. Dr. Oliver Findl, MBA · starts Mar 27, 2026
- Anterior Segment Anatomy Assessed by Swept-Source OCT in Ocular Surgery PatientsNCT07903454 · Not reported · Nanfang Hospital, Southern Medical University · starts May 1, 2026
- Trial Comparing miLOOP Device Assisted Phacoemulsification vs Standard Surgery for Dense Cataracts: Effects on…NCT07898007 · Not applicable · Universiti Kebangsaan Malaysia Medical Centre · starts Oct 1, 2024
- Objective Depth-of-Focus Changes During Light Adjustable Lens UV AdjustmentsNCT07868003 · Not reported · Clarity Eye Institute · starts Nov 2, 2026
- Pilot Study: Feasibility and Usability of a Head-Mounted Spatial Computing Device for Intraoperative Visualization…NCT07825337 · Not reported · Eric Rosenberg · starts Aug 30, 2026
- Evaluation of Vitreous Modifications After Cataract SurgeryNCT07816887 · Not reported · University of Trieste · starts Jul 30, 2026
- Evaluation of LacrifillNCT07796178 · Phase 4 · Eye Research Associates, LLC · starts Sep 2, 2026
- Guangke Lenses in Congenital CataractNCT07778797 · Not applicable · Eye & ENT Hospital of Fudan University · starts Aug 6, 2025
Approved 6
- NepafenacCyclooxygenase inhibitor
- KetorolacCyclooxygenase inhibitor
- BromfenacCyclooxygenase inhibitor
- DiclofenacCyclooxygenase inhibitor
- AcetylcholineMuscarinic acetylcholine receptor M3 agonist
- CarbamoylcholineMuscarinic acetylcholine receptor M3 agonist
Phase 3 12 of 22
- DexamethasoneGlucocorticoid receptor agonist
- Prednisolone acetateGlucocorticoid receptor agonist
- LevofloxacinDNA gyrase inhibitor
- Tobramycin70S ribosome inhibitor
- Clobetasol propionateGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- MoxifloxacinTopoisomerase IV inhibitor
- AspirinCyclooxygenase inhibitor
- AcetohexamideSulfonylurea receptor 1, Kir6.2 blocker
- TetracaineSodium channel alpha subunit blocker
- DifluprednateGlucocorticoid receptor agonist
- Loteprednol etabonateGlucocorticoid receptor agonist
Phase 2 5
- Triamcinolone acetonideGlucocorticoid receptor agonist
- CiprofloxacinBacterial DNA gyrase inhibitor
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- Citric acid
Phase 1 or earlier 3
- GatifloxacinDNA gyrase inhibitor
- BesifloxacinTopoisomerase IV inhibitor
- MethylcelluloseBulk-forming laxative
How its trials ended
1,571 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 232 whose ending is known, 47% met their primary endpoint, 3% missed it and 49% stopped early.
- Completed, result not reported87155%
- Status unknown27317%
- Ongoing19512%
- Met its primary endpoint1107%
- Stopped: other or unclear684%
- Stopped: enrollment or feasibility221%
- Stopped: sponsor or business decision151%
- Missed its primary endpoint81%
- Stopped: lack of efficacy5<1%
- Stopped: funding3<1%
- Stopped: safety1<1%
| Oct 16, 2018 | A randomized controlled trial comparing safety and efficacy of dexamethasone 0.1% and loteprednol etabonate 0.5% after cataract surgeryLotemax (loteprednol) / Maxidex (dexamethasone) | Bausch & Lomb | Pending |
| Jan 4, 2018 | Economic impact of dropless therapy versus usual care for cataract surgery: a real-world studyTriamcinolone acetonide-moxifloxacin | Imprimis Pharmaceuticals | Ongoing |
| Dec 21, 2017 | A randomized, single-blind, cross-over study of loteprednol etabonate in adults undergoing bilateral cataract surgeryLoteprednol | Sandoz | Closed |
| Jun 28, 2016 | Comparative effectiveness and safety of 2 dosing regimens of loteprednol gel 0.5% and bromfenac 0.07% solution to control inflammation and pain after cataract…Besifloxacin/ Loteprednol/ Bromfenac | Dr Sohel Somani | Pending |
| Mar 22, 2016 | The effect of brimonidine on the development of subconjunctival hemorrhage following femtosecond laser assisted cataract surgeryBrimonidine | Dr. Eric S. Tam | Pending |
| May 18, 2011 | YelloxBromfenac | Bausch + Lomb Ireland Limited | EMA ↗ |
| Dec 11, 2007 | NevanacNepafenac | Novartis Europharm Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA